American Journal of Kidney Diseases
Volume 49, Issue 6 , Pages 801-813 , June 2007

Parathyroidectomy Versus Cinacalcet Hydrochloride–Based Medical Therapy in the Management of Hyperparathyroidism in ESRD: A Cost Utility Analysis

  • Rajeev Narayan, MD

      Affiliations

    • Division of Nephrology, Walter Reed Army Medical Center, Washington, DC
    • ,
  • Robert M. Perkins, MD

      Affiliations

    • Division of Nephrology, Walter Reed Army Medical Center, Washington, DC
    • ,
  • Elizabeth P. Berbano, MD, MPH

      Affiliations

    • Division of Internal Medicine, Walter Reed Army Medical Center, Washington, DC
    • ,
  • Christina M. Yuan, MD

      Affiliations

    • Division of Nephrology, Walter Reed Army Medical Center, Washington, DC
    • ,
  • Robert T. Neff, MD

      Affiliations

    • Division of Nephrology, Walter Reed Army Medical Center, Washington, DC
    • ,
  • Eric S. Sawyers, MD

      Affiliations

    • Division of Nephrology, National Naval Medical Center, Bethesda, MD
    • ,
  • Fred E. Yeo, MD

      Affiliations

    • Division of Nephrology, National Naval Medical Center, Bethesda, MD
    • ,
  • Gwenaelle M. Vidal-Trecan, MD, PhD

      Affiliations

    • Departement de Sante Publique, University of Paris Descartes, Faculte de Medecine Paris 5, Paris, France.
    • ,
  • Kevin C. Abbott, MD, MPH

      Affiliations

    • Division of Nephrology, Walter Reed Army Medical Center, Washington, DC
    • Corresponding Author InformationAddress correspondence to Kevin C. Abbott, MD, MPH, Chief, Nephrology, Walter Reed Army Medical Center, Washington, DC 20307-5001.

Received 23 August 2006 ,Accepted 19 March 2007.

References 

  1. Owda A, Elhwairis H, Narra S, Towery H, Osama S. Secondary hyperparathyroidism in chronic hemodialysis patients: Prevalence and race. Ren Fail. 2003;25:595–602
  2. Locatelli F. The need for better control of secondary hyperparathyroidism. Nephrol Dial Transplant. 2004;19(suppl 5):SV15–SV19
  3. Lorenzo V, Martin-Malo A, Perez-Garcia R, et al. Prevalence, clinical correlates and therapy cost of mineral abnormalities among haemodialysis patients: A cross-sectional multicentre study. Nephrol Dial Transplant. 2006;21:459–465
  4. de Francisco AL. Secondary hyperparathyroidism: Review of the disease and its treatment. Clin Ther. 2004;26:1976–1993
  5. Kestenbaum B, Andress DL, Schwartz SM, et al. Survival following parathyroidectomy among United States dialysis patients. Kidney Int. 2004;66:2010–2016
  6. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005;68:1793–1800
  7. Wholesale Drug Prices. Chesterbrook, PA: AmerisourceBergen Corporation; 2006;(provided by Walter Reed Pharmacy), October
  8. Moe SM, Cunningham J, Bommer J, et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant. 2005;20:2186–2193
  9. Lindberg JS, Culleton B, Wong G, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study. J Am Soc Nephrol. 2005;16:800–807
  10. Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350:1516–1525
  11. Dong BJ. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism. Clin Ther. 2005;27:1725–1751
  12. Detsky AS, Naglie G, Krahn MD, Redelmeier DA, Naimark D. Primer on medical decision analysis: Part 2—Building a tree. Med Decis Making. 1997;17:126–135
  13. Sejean K, Calmus S, Durand-Zaleski I, et al. Surgery versus medical follow-up in patients with asymptomatic primary hyperparathyroidism: A decision analysis. Eur J Endocrinol. 2005;153:915–927
  14. Mokrzycki MH, Singhal A. Cost-effectiveness of three strategies of managing tunnelled, cuffed haemodialysis catheters in clinically mild or asymptomatic bacteraemias. Nephrol Dial Transplant. 2002;17:2196–2203
  15. Saab S, Brezina M, Gitnick G, Martin P, Yee HF. Hepatitis C screening strategies in hemodialysis patients. Am J Kidney Dis. 2001;38:91–97
  16. Strippoli GF, Palmer S, Tong A, Elder G, Messa P, Craig JC. Meta-analysis of biochemical and patient-level effects of calcimimetic therapy. Am J Kidney Dis. 2006;47:715–726
  17. Richards ML, Wormuth J, Bingener J, Sirinek K. Parathyroidectomy in secondary hyperparathyroidism: Is there an optimal operative management?. Surgery. 2006;139:174–180
  18. Goodman WG, Frazao JM, Goodkin DA, Turner SA, Liu W, Coburn JW. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int. 2000;58:436–445
  19. Goodman WG, Hladik GA, Turner SA, et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol. 2002;13:1017–1024
  20. Lindberg JS, Moe SM, Goodman WG, et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int. 2003;63:248–254
  21. Quarles LD, Sherrard DJ, Adler S, et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol. 2003;14:575–583
  22. Harris RZ, Padhi D, Marbury TC, Noveck RJ, Salfi M, Sullivan JT. Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily. Am J Kidney Dis. 2004;44:1070–1076
  23. Dotzenrath C, Cupisti K, Goretzki E, et al. Operative treatment of renal autonomous hyperparathyroidism: Cause of persistent or recurrent disease in 304 patients. Langenbecks Arch Surg. 2003;387:348–354
  24. Qunibi WY, Hootkins RE, McDowell LL, et al. Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int. 2004;65:1914–1926
  25. Centers for Medicare & Medicaid Services: Average National Reimbursement Figures. Washington, DC: Department of Health and Human Services; 2005;(provided by WRAMC DRG Coordinator)
  26. Ruda J, Stack BC, Hollenbeak CS. The cost-effectiveness of sestamibi scanning compared to bilateral neck exploration for the treatment of primary hyperparathyroidism. Otolaryngol Clin North Am. 2004;37:855–870x-xi
  27. McHenry CR, Wilhelm SM, Ricanati E. Refractory renal hyperparathyroidism: Clinical features and outcome of surgical therapy. Am Surg. 2001;67:310–316discussion, 316-317
  28. Whiting JF Transplantation Outcomes Research Group. Standards for economic and quality of life studies in transplantation. Transplantation. 2000;70:1115–1121
  29. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care. 2000;38:583–637
  30. McFarlane PA, Bayoumi AM, Pierratos A, Redelmeier DA. The quality of life and cost utility of home nocturnal and conventional in-center hemodialysis. Kidney Int. 2003;64:1004–1011
  31. Furth SL, Garg PP, Neu AM, Hwang W, Fivush BA, Powe NR. Racial differences in access to the kidney transplant waiting list for children and adolescents with end-stage renal disease. Pediatrics. 2000;106:756–761
  32. Abbott KC, Glanton CW, Agodoa LY. Body mass index and enrollment on the renal transplant waiting list in the United States. J Nephrol. 2003;16:40–48
  33. US Renal Data System. USRDS 2005 Annual Data Report. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2005;
  34. Manns B, Stevens L, Miskulin D, Owen WF, Winkelmayer WC, Tonelli M. A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int. 2004;66:1239–1247
  35. White CA, Jaffey J, Magner P. Cost of applying the K/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis patients. Kidney Int. 2007;71:312–317

 Originally published online as doi:10.1053/j.ajkd.2007.03.009 on May 7, 2007.

 Disclaimer: The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of the Army or the Department of Defense.

 Support: None. Potential conflicts of interest: None.

PII: S0272-6386(07)00644-0

doi: 10.1053/j.ajkd.2007.03.009

American Journal of Kidney Diseases
Volume 49, Issue 6 , Pages 801-813 , June 2007

Article Tools

* Image Usage & Resolution